AstraZeneca nixes $8B Sobi buyout over fears a former drug would be sold to rivals — report

Max Gelman

Senior Editor

AstraZeneca has reportedly tanked a deal that would have taken high-profile rare disease company Sobi private over fears its respiratory drugs would fall into the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca nixes $8B Sobi buyout over fears a former drug would be sold to rivals — report

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA approves first drug to treat ultra-rare lipid storage disease

How AI can address ongoing challenges in the life sciences industry

As­traZeneca nix­es $8B So­bi buy­out over fears a for­mer drug would be sold to ri­vals — re­port

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

AstraZeneca nixes $8B Sobi buyout over fears a former drug would be sold to rivals — report